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Abstract: The novel coronavirus disease (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has engulfed the world, affecting more than 180 countries.
As a result, there has been considerable economic distress globally and a significant loss of life. Sadly,
the vulnerable and immunocompromised in our societies seem to be more susceptible to severe
COVID-19 complications. Global public health bodies and governments have ignited strategies and
issued advisories on various handwashing and hygiene guidelines, social distancing strategies, and,
in the most extreme cases, some countries have adopted “stay in place” or lockdown protocols to
prevent COVID-19 spread. Notably, there are several significant risk factors for severe COVID-19
infection. These include the presence of poor nutritional status and pre-existing noncommunicable
diseases (NCDs) such as diabetes mellitus, chronic lung diseases, cardiovascular diseases (CVD),
obesity, and various other diseases that render the patient immunocompromised. These diseases are
characterized by systemic inflammation, which may be a common feature of these NCDs, affecting
patient outcomes against COVID-19. In this review, we discuss some of the anti-inflammatory
therapies that are currently under investigation intended to dampen the cytokine storm of severe
COVID-19 infections. Furthermore, nutritional status and the role of diet and lifestyle is considered,
as it is known to affect patient outcomes in other severe infections and may play a role in COVID-19
infection. This review speculates the importance of nutrition as a mitigation strategy to support
immune function amid the COVID-19 pandemic, identifying food groups and key nutrients of
importance that may affect the outcomes of respiratory infections.
Keywords: coronavirus; COVID-19; SARS-CoV-2; inflammation; infection; anti-inflammatory; nutrition;
vitamin C; vitamin D; zinc; noncommunicable diseases
1. Introduction—Current Status
Since late 2019, the world has come to terms with the fact that it is facing a major public health
crisis against the novel coronavirus disease termed COVID-19 caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). As of May 10th, there are over four million confirmed cases of
COVID-19 and almost 280,000 deaths globally [1]. The first known case of COVID-19 originated from
the city of Wuhan in Hubei Province, China. From there, it has spread to every inhabited continent
worldwide. The virus originates from a large class of viruses known as β-coronaviruses common in
nature, with many potential natural primary, intermediate, and final hosts [2]. SARS-CoV-2 (Figure 1)
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is an enveloped positive-sense RNA virus that typically affects the respiratory system, whereby the
main known route of transmission occurs due to the spread of droplets generated when an infected
person sneezes or coughs or through other mucus environments, including saliva or discharge from
the nose [3]. SARS-CoV-2 gains entry to the cell via the angiotensin-converting enzyme 2 (ACE2)
receptor [4–12], whereby it predominantly infects the lower respiratory tract, binding to ACE2 on
alveolar epithelial cells [13]. Upon binding, there is a subsequent response of the immune system via
inflammation-related manifestations and recruitment of antigen-presenting cells [10–12]. The infectious
capacity of the virus in conjunction with the high fatality rates (1%–>5%) has left the world scrambling
to bring the pandemic under control [6–9,14,15]. COVID-19 infection can manifest as an asymptomatic
infection, or patients can present with a mild upper respiratory tract illness that may include a cough,
chills, fever, fatigue, and shortness of breath [15]. In severe cases, the most common complications are
sepsis, acute respiratory distress syndrome (ARDS), heart failure, and septic shock. However, severe
viral pneumonia with respiratory failure can potentially lead to death [16]. Multiple organ dysfunction
is likely attributable to uncontrolled acute inflammation and cytokine storm release [10–12,17–19].
As our knowledge of the disease is evolving, it is clear that other symptoms are being identified,
including chilblains [20], sudden anosmia or ageusia [21], and even stroke [22].
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Damage to the pulmonary interstitial arteriolar walls indicates that an inflammatory response plays 
an important role throughout the course of the disease, despite the pathogenic effect of the virus 
[10,11]. Apart from nonspecific inflammatory responses such as edema and inflammatory cell 
infiltration, severe exfoliation of alveolar epithelial cells, alveolar septal widening, damage to alveolar 
septa, and alveolar space infiltration has been detected in a distinctly organized manner [10,11]. Thus, 
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[10]. 
Apart from respiratory failure, other common features amongst critical COVID-19 patients 
include a sudden decline of the patient’s health status approximately two weeks after onset [11], 
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cells in peripheral blood, extremely high levels of inflammatory response due to the proinflammatory
cytokine storm, atrophy of the spleen and lymph nodes, along with reduced lymphocytes in lymphoid
organs, hypercoagulability, thrombosis, and multiple organ damage [11,24]. These are just a selection of
the clinical manifestations that occur as the medical community begins to learn more as the pandemic
continues to grow.
It is therefore apparent that a viral infection-related inflammation and the subsequent cytokine
storm in severe cases plays a crucial role in patient outcomes [10–12,17]. Furthermore, the coexistence
of noncommunicable chronic diseases (NCDs) in COVID-19 patients may aggravate and intensify the
inflammatory pathology and increase the risk for adverse outcomes and mortality [25]. This is evident
in those at high risk of CVD who may also be at high risk for severe COVID-19 infections due to high
angiotensin-converting enzyme 2 (ACE2) expression observed in these patients [4,7–9]. Currently, there
is a worldwide effort to rapidly diagnose and isolate COVID-19 patients, while scientists congruently
search for and repurpose therapies and interventions that are able to counter the most severe effects
of the disease [26]. While some therapeutic agents look promising, there is currently no evidence of
safety and efficacy in human trials for any proposed treatment for COVID-19 [27].
Therefore, an understanding of the mechanisms involved in these manifestations may facilitate
the development of targeted anti-inflammatory therapies. However, it is important to recognize that
our understanding of the pathomechanisms of COVID-19 are continually evolving. Equally, it is
important to determine prophylactic interventions to prevent or lower the incidence of infection.
To date, the most effective mitigation strategies being implemented globally consist of encouraging
standard public health practices such as regular hand washing with soap, wearing a face mask [28],
and covering a cough with your elbow [29], along with introducing social distancing measures,
“stay in place” guidelines, expansive testing, and contact tracing [30,31]. However, it has been
postulated that a healthy nutritional status may support immune function and prevent the onset of a
severe infection [32–35], which leads to the question of whether maintaining a healthy nutritional status
is warranted at this time to prime the immune systems of individuals not infected with COVID-19.
In light of the ongoing public health emergency, a review of pharmacological and nutritional
strategies to support the optimization of immune health seems both timely and worthwhile. Therefore,
the aims of this review are to give an overview of some of the anti-inflammatory therapies that are
under investigation and intended to dampen the inflammatory response in severe COVID-19 infections
and to outline dietary considerations implicated in immune function and respiratory illness outcomes,
as they may influence patient outcomes in severe COVID-19 infections.
2. Mechanisms of the Uncontrolled Inflammatory Response and Cytokine Storm during
Disease Progress
The first step in the host cell viral entry is the binding of the viral trimeric spike protein of
SARS-CoV-2 to the human receptor angiotensin-converting enzyme 2 (ACE2), which is similar to
SARS-CoV-1 infection mechanisms [6–9]. Although sharing a close evolutionary relationship with
SARS-CoV-1, the receptor-binding domain of SARS-CoV-2 differs in several key amino acid residues,
allowing for a stronger binding affinity with the human ACE2 receptor, which may account for the
greater pathogenicity of SARS-CoV-2 [7,36]. Although ACE2 expression correlates with susceptibility
to SARS-CoV-1 infection, the relationship between ACE2 expression levels and the susceptibly to
SARS-CoV-2 infection remains unclear [37].
When SARS-CoV-2 infects the respiratory tract, it can cause mild respiratory infections or severe
acute respiratory syndrome with consequent inflammatory responses [10–12]. During COVID-19
infection, the virus infects antigen-presenting cells, macrophages, and dendritic cells, which present
SARS-CoV-2 antigens to T cells, leading to T cell activation, differentiation, and a subsequent enormous
cytokine release [10]. The host innate immune system detects viral infections by using pattern
recognition receptors (PRRs), including Toll-like receptors (TLR), to recognize pathogen-associated
molecular patterns (PAMPs) like lipoproteins, proteins, lipids, and nucleic acids of viral origin [10,38].
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Subsequently, there is the activation of transcription factors NF-kB, IRF3, and mitogen-activated
protein kinases (MAPKs) pathways that induce the expression of inflammatory factors [39]. For example,
the binding of SARS-CoV-2 to the TLR causes the release of pro-IL-1β, which is cleaved by caspase-1,
followed by inflammasome activation and production of active mature IL-1β, which is a mediator of
lung inflammation, fever, and fibrosis [12].
Mast cells (MCs) that are present in the submucosa of the respiratory tract and in the nasal cavity
represent a barrier of protection against microorganisms, and they can be virus-activated. Activation
of MCs release early inflammatory molecules, such as histamine and proteases, while late activation
triggers the production of proinflammatory IL-1 family members, including IL-1, IL-6, and IL-33 [4].
These processes lead to T cell activation and differentiation, including the production of cytokines
of various T cell subsets, followed by a massive release of cytokines involved in immune response
amplification [10,40]. T cells of the adaptive immune system play an important antiviral role by
balancing the battle against pathogens and the risk of overwhelming inflammation or developing
autoimmunity [41]. Helper T cells such as the CD4+ promote the production of virus-specific antibodies
by activating T-dependent B cells, while other T cells such as the CD8+ are cytotoxic and can kill
viral-infected cells [10]. In addition, T helper cells produce proinflammatory cytokines and chemokines
via the NF-kB signaling pathway, which, in turn, recruits lymphocytes and leukocytes, such as
monocytes and neutrophils, to the site of infection, with a subsequent secretion of large quantities of
chemokines and cytokines from all these immune cells to amplify the inflammatory response to the
virus infection [10,42].
The extensive and uncontrolled release of proinflammatory cytokines is termed the cytokine
storm. Clinically, the cytokine storm commonly presents as systemic inflammation and multiple organ
failure [11]. Clinical evidence has shown that severe COVID-19 patients have an elevated cytokine
profile reminiscent of a cytokine storm as previously observed in SARS-CoV-1 and the Middle East
respiratory syndrome (MERS) [11]. The level of inflammatory factors in patients with COVID-19 are
increased, among which are IL-1RA, IL-1B, IL-7, IL-8, IL-9, IL-10, granulocyte-macrophage colony
stimulating factor (GM-CSF), IFN-γ, fibroblast growth factor (FGF), granulocyte-colony stimulating
factor (G-CSF), interferon-γ-inducible protein (IP10), macrophage inflammatory protein 1 alpha
(MIP1A), platelet-derived growth factor (PDGF), monocyte chemoattractant protein (MCP1), vascular
endothelial growth factor (VEGF), and tumor necrosis factor (TNF-α). Furthermore, levels of IL-2, IL-6,
IL-7, IL-10, IP10, G-CSF, MCP1, MIP1A, and TNF-α were higher in critically ill patients with COVID-19
than that in mild groups [11,12,43].
In the majority of severe COVID-19 patients, the cytokine storm was associated with high levels
of erythematosus sedimentation rate (ESR) and C-reactive protein (CRP), which were associated
with ARDS, hypercoagulation, and disseminated intravascular coagulation (DIC), presenting as
thrombocytopenia, thrombosis, and gangrene of the limbs. It is possible that the cytokine storm may
exacerbate lung damage [11,44]. Blanco-Melo et al. [45] determined that the unique inappropriate
inflammatory response of COVID-19 is due to the low levels of type I and II interferons in conjunction
with an elevated expression of IL-6 and increased chemokines. They hypothesize that the enhanced
inflammatory response, along with a reduced innate antiviral defense, may be the “defining and
driving feature” of COVID-19 infections.
Although the lungs are considered the main target organ of SARS-CoV-2, the virus can affect many
other organs, including the heart and blood vessels, the kidneys, the gut, and brain, through various
mechanisms [46]. It has been widely proposed that one of the ways the virus can critically affect these
organs is through an intense inflammatory reaction, while other mechanisms have yet to be elucidated.
For instance, it is now documented that COVID-19 patients may be predisposed to arterial and venous
thromboembolisms due to excessive inflammation, diffuse intravascular coagulation, and hypoxia.
In a Dutch study of COVID-19 patients, one-third exhibited blood clots [47]. Therefore, antiplatelet
agents may be considered to treat COVID-19. Overall, considering inflammation plays a significant
role in COVID-19 pathology, it would seem logical that it would be important to control cytokine
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production, given that they are responsible for the accumulation of immune cells and fluids. As such,
anti-inflammatory treatments may hold promise for the management of COVID-19 complications.
3. Current Knowledge of COVID-19 Treatment and Anti-Inflammatory Approaches
Classic first-line antiviral treatments are a potential therapeutic against COVID-19, which, when
concomitant with organ function support, are very important to reduce mortality for mild and
critical patients [11,48]. Antiviral therapy against SARS-CoV-2 consists of using different polymerase
inhibitor drugs that are currently on the market and approved for use against other viruses; these
include Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir [48]. These antiviral drugs
have previously exhibited anti-inflammatory properties, either individually or combined as highly
active antiviral therapies. However, the long-term use of some of these antiviral therapeutics against
other persistent viral infections has been associated with inflammation-related cardiovascular side
effects [49,50].
Researchers are also targeting inflammation through the investigation of immunomodulatory
and anti-inflammatory therapies to reduce systemic inflammation before the onset of multiorgan
dysfunction [11,51]. Therefore, biological agents targeting cytokines expression and specific cytokine
antagonists, such as IL-6R monoclonal antibodies, TNF inhibitors, IL-1 antagonists, Janus kinase
inhibitor (JAK) inhibitors, etc., have been considered [11]. Adopting an approach against specific
cytokines entails the danger of only inhibiting one aspect of the inflammatory pathways involved.
As a consequence, it may not be very effective in curbing the cytokine storm in COVID-19, as various
cytokine pathways are of significant importance, and immunosuppression may actually compromise
host defenses [52,53]. Furthermore, some of these specified anti-inflammatory medications, such as
JAK inhibitors, may also block the production of the antiviral interferons such as the INF-a, which may
have negative consequences for the immune response [11,54].
Researchers are also investigating the possible effects of antimalarial drugs such as chloroquine and
hydroxychloroquine against SARS-CoV-2. These molecules are generally prescribed for autoimmune
diseases such as systemic lupus erythematosus and rheumatoid arthritis in patients whose disease
status has not improved with other treatments. However, chloroquine and hydroxychloroquine
possess a broad spectrum of antiviral effects against several viral infections, including coronaviruses
such as SARS-CoV-1 [11,37,48,49,55,56]. In vitro experiments in China identified chloroquine as
a promising therapeutic against SARS-CoV-2 [56,57], while the immunomodulatory effects of its
derivative hydroxychloroquine may be more effective at targeting the cytokine storm that occurs in the
late phase of critically ill COVID-19 infected patients, with less side effects [55,58].
Hydroxychloroquine interferes with lysosomal activity and autophagy and alters transcription
and signaling pathways, which can result in the modulation of cytokine production [59], all of which
are postulated to dampen the effects of the proinflammatory cytokine storm of severe COVID-19
patients. Furthermore, hydroxychloroquine has been reported to have better outcomes when combined
with other drugs, such as antibiotics like azithromycin, or drugs used for rheumatoid arthritis, such
as tocilizumab/atlizumab, in addition to the standard medical management for septic shock and
ARDS [60]. Notably, some antibiotics, including azithromycin, have exhibited anti-inflammatory
potency [51,61,62], while tocilizumab/atlizumab contains a humanized monoclonal antibody against
the IL-6 receptor; thus, it is mainly used for reducing inflammation during autoimmune disorders [63].
Hydroxychloroquine, in combination with azithromycin, has been particularly focused upon due
to the results of a French study where 26 COVID-19 patients received the combination treatment versus
control groups. However, there were several issues with the study design, including its small sample size,
the fact that the control groups were from different hospitals, the study was not blinded, and a myriad
of other issues [64]. While the study provided an indication that hydroxychloroquine was worth further
investigation, its results have been blown out of proportion in the media. Hydroxychloroquine has even
been prematurely touted as a “game-changer” by President Donald Trump of the United States, who has
admonished that he may even consider taking this untested drug against COVID-19 [65]. Some countries
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have allowed compassionate use of these drugs [66,67]. The promotion of hydroxychloroquine or
chloroquine without substantial evidence of randomized, controlled trials is a significant safety and
efficacy concern and requires further intensive investigation [68–70]. Currently, a study from the United
States Veterans Health Administration indicated that patients administered hydroxychloroquine alone
or in combination with azithromycin were no less likely to require mechanical ventilation and had
higher mortality when on hydroxychloroquine alone versus the standard treatment [71]. This example
demonstrates the necessity for world leaders to consult with their experts prior to promoting unproven
medications against SAR-CoV-2 as a matter of public safety until further research is conducted.
Several researchers mention the relationship of anti-CVD-related drugs with COVID-19. Indeed,
there is a focus on the anti-inflammatory drug colchicine, which has been previously used effectively
against cardiovascular disorders [72]. Since ACE2 is implicated in COVID-19 infection, the role of
angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) of the ACE2
receptor and its rennin-angiotensin system, which are typically used for hypertension, has recently
been evaluated [7–9,37]. ACEIs/ARBs perform a protective role in the cardiovascular system by also
increasing the expression ACE2 in the heart [37]. However, the impact of ACEIs/ARBs on ACE2
in other organs, especially whether they could influence the expression level and activity of ACE2
in the lungs, with a subsequently higher susceptibility to SARS-CoV-2 infection, remains unknown.
Thus, if ACEIs/ARBs have the capacity to upregulate the expression and activity of ACE2 in the lungs,
they may play a dual role in COVID-19. On one hand, the higher level of ACE2 might increase the
susceptibility of cells to SARS-CoV-2 viral host entry and propagation, whereas, on the other hand,
the activation of ACE2 might ameliorate the acute lung injury induced by SARS-CoV-2 [37,73,74].
Despite these concerns, the European Society of Cardiology recommends that patients continue
their usual antihypertensive medications due to lack of evidence [75]. This also may have dietary
implications due to the modulatory effects dietary patterns can have on hypertension but also due to
the fact that some foods are associated with high levels of ACE inhibitory peptides [76]. Thus, further
research is required to investigate the role of ACE2 activation, expression, and its related pathways
in COVID-19.
As aforementioned, implementing an anti-inflammatory strategy is challenging, as it is not yet
clear if any specific features of the immune response can be inhibited directly without compromising a
patient’s overall immune defense [52]. It is important to determine the optimum method to reduce
inflammation. Further research is also required to gain an understanding of the temporal features
of the COVID-19 inflammatory response and to determine at what stage of the infection should
pharmaceutical treatments be administered. Similarly, an understanding of the dosing and sexual
dimorphism in drug metabolism and disease presentation is required. Likewise, ethnicity may be a
determining factor in severe COVID-19 infections that requires further investigation [77,78].
Furthermore, considering an increased risk of clot development can turn mild cases into more
severe and life-threatening emergencies, a preventative approach targeting thrombosis should also be
considered [47], particularly those that may also target inflammation [79]. Reactive oxygen species
(ROS) also play a crucial role in the inflammatory response. As such, utilizing compounds with
antioxidant properties may also be considered to reduce the cytokine storm induced by the viral
infection [80]. Indeed, antioxidative therapies are being considered for ameliorating cardiac injuries in
critically ill COVID-19 patients [81].
Among other measures, the nutritional status of an infected patient should also be considered, as
nutritional deficiencies may increase a patient’s risk to developing a severe infection of COVID-19 [82].
Introducing nutritional interventions should not be overlooked due to their potential for beneficial
clinical outcomes [83]; in particular, consideration must be given to intensive care unit (ICU) patients [84].
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4. Noncommunicable Diseases and COVID-19—The Link between Immunity and Nutrition
On 23rd March 2020, the World Health Organization (WHO) issued guidelines to highlight that
those diagnosed with noncommunicable diseases (NCDs) may be more susceptible to developing
COVID-19 (Figure 2) [25,85].
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The link between viral infection severity and NCDs has been observed in other viral infections,
such as influenza [86]. Chronic and unresolved inflammation is implicated in the onset, progression,
and development of NCDs [87,88]. Furthermore, it is thought that underlying systemic inflammation
may exacerbate COVID-19 infection [85]. For instance, in COVID-19 patients with underlying CVD,
the respiratory symptoms of infection seem to be more severe [89]. Data from the United States Centers
for Disease Control and Prevention (CDC) demonstrates the high risk of mortality in individuals with
pre-existing health conditions [90]. Considering patients with pre-existing conditions such as diabetes
and high blood pressure exhibit damage to the blood vessels, the existence of increased thrombotic
complications in COVID-19 may account for the higher risk of serious disease in these patients [46].
Certainly, diabetes is a significant risk factor for COVID-19 [91] and is associated with a two-fold
increase in mortality and potential disease severity [92].
Generally, where possible, an effective strategy to reduce one’s risk of developing NCDs is to
control the activities of inflammatory mediators via modifiable risk factors such as diet, exercise,
and healthy lifestyle choices [87,93]. Only the adoption of a long-term and consistent dietary pattern
benefits human health. Conversely, adoption of an unhealthy diet and lifestyles is associated with
low-grade inflammation and increased oxidative stress, which could lead to the development of
NCDs [87,94]. Certainly, there is considerable evidence that the food and nutrients we consume affect
how our immune system functions [34,95,96]. The role of nutrition amidst the current global pandemic
will be discussed in Section 5.
Some reports [25,90] have suggested that a higher body mass index (BMI) or excess adiposity carry
risk factors for complications arising from COVID-19 infection. This may be due to a higher prevalence
of pulmonary problems in obese populations relative to their healthy weight counterparts [97]. Patients
with obesity and comorbidities that compromise their heart or lung function are likely at higher risk
for developing severe diseases with COVID-19 [14], much like the nonobese patients with those risk
factors. Maintaining a body weight and composition in line with recommendations [98] for stature
and gender (among other considerations, such as comorbid disease or athletic discipline) is prudent.
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5. Immunomodulatory and Anti-Inflammatory Potential of Maintaining a Healthy Nutritional Status
Nutritional status can have a significant impact on an individual’s overall health, the reduction
of NCDs, and a reduced susceptibility to developing infections. In this section, the beneficial effects
of a healthy diet are discussed in relation to the current COVID-19 pandemic. However, it must be
noted that, to date, there are no known evidence-based therapeutics or treatment strategies available to
prevent the incidence or severity of COVID-19 infection. Likewise, there is no single food or natural
remedy that has been proven to prevent COVID-19 infections, which has been made clear by the
WHO [99]. However, learning from previous research in relation to other viral infections, it is clear
that nutritional status plays a significant role in patient outcomes [100]. The presence of comorbidities
in COVID-19 patients is currently a significant concern [25], which leads to the question of whether
the nutritional status of these patients is a concern. Likewise, for those not affected, could following
a diet characterized by anti-inflammatory properties potentially benefit or prevent severe infections
in patients with comorbidities who contract COVID-19? In general, how important is it to follow a
healthy diet currently for the general population? There are various diets and nutrients that potentially
impart anti-inflammatory and immunomodulatory properties on diseases, including cardiovascular
diseases, lung diseases, and numerous NCDs, without risking immunosuppression [101–104]; thus,
diet is worthy of significantly more research.
Due to its safety and ease of application, nutrition is well-placed to have a key role in the
challenge of “keeping healthy people healthy”. Moderate-quality evidence suggests that dietary
patterns and individual nutrients can influence systemic markers of immune functions. However,
the complexity of the interaction (nutrition and immunology) necessitates further research in advance
of population–based dietary recommendations. At a minimum, the attainment of reference nutrient
intakes (RNIs) or recommend daily allowance (RDA) for those nutrients thought to have a role in
supporting immune functions is recommended at this time. These nutrients and their potential roles in
either immune functions or respiratory tract infections are discussed below.
Maintaining nutritional status at this time is significant, since the battle against COVID-19 will
likely last longer than what was initially anticipated. It is also apparent that social isolation and
mitigation measures such as “stay at home” orders will last for a prolonged period for millions of
people around the world. Therefore, in order to prevent the development or exacerbation of NCDs,
which are currently a significant burden on global health systems [105], and to maintain a healthy
immune system, special attention must be given to maintaining a healthy diet, lifestyle, exercise regime,
and minimal stress as much as safely possible at this difficult time [106].
Indeed, it is particularly important at this time to consider our elderly communities, as the elderly
are not only predisposed to NCDs, but they are also vulnerable to the increased risk of malnourishment,
infections, and COVID-19 [90]. In fact, age itself is a risk factor for developing COVID-19 [107]. This is
due to a functional decline of the immune system with age known as immunosenescence [108,109].
Malnourishment can occur for several reasons, including poor socioeconomic conditions, mental
status, social status, and a host of other multifactorial issues [110]. Indeed, often, there are nutritional
deficiencies of calcium, vitamin C, vitamin D, folate, and zinc amongst elderly populations [111].
Malnourishment can exasperate an impaired immune system in the elderly, making them susceptible to
infections [112]. A healthy, balanced diet can offer the necessary macro- and micronutrients, prebiotics,
probiotics, and symbiotics in the elderly that can restore and maintain immune cell function, thus
increasing protection against chronic inflammation-related NCDs, on the one hand, and potential
infections and related inflammatory manifestations on the other hand [87,113]. The foods, food groups,
and nutrients described in this review have been chosen due to their potential anti-inflammatory
and immunomodulatory properties. However, there are other nutrients, etc., worthy of further
investigation, including vitamin A, selenium, and various probiotics and nutraceuticals [114,115].
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5.1. Dietary Patterns
5.1.1. Mediterranean Diet
Various dietary patterns have been linked to the risk of inflammatory conditions [116] and
respiratory disease [117]. One diet synonymous with anti-inflammatory properties is the Mediterranean
diet, which is characterized by a relatively high dietary intake of minimally processed fruit, vegetables,
legumes, olive oil, whole grains, nuts, and monounsaturated fats, followed by low-to-moderate
consumptions of fermented dairy products, fish, poultry, wine, and, lastly, low consumptions
of processed and red meats [87,118]. A balanced diet rich in these foods is associated with
anti-inflammatory and immunomodulatory compounds, including essential vitamins (C, D, and E)
and minerals (zinc, copper, calcium, etc.), that affect a person’s nutritional status [119].
Several foods associated with the Mediterranean diet and other healthy dietary patterns contain
bioactive compounds that go beyond just vitamins and minerals, including bioactive phenolic
compounds; polar lipids; and peptides with potent anti-inflammatory, antithrombotic, and antioxidant
properties. These molecules can synergistically act to prevent and protect against inflammatory
manifestations and associated thrombotic and ROS-related complications [87,120–124].
Therefore, healthy dietary patterns such as the Mediterranean diet or similar are beneficial against
NCDs but, potentially, also against infections such as COVID-19 due to their effects on immune
health [87,125,126]. The traditional Mediterranean diet has been found to have protective effects for
allergic respiratory diseases in epidemiological studies [127] and for inflammatory conditions [116,128].
Overall, much of the benefits of the Mediterranean diet has to do with the high intake of a wide
range of bioactive compounds that come from all aspects of the diet [87,129,130] and the relatively low
intake of overly processed foods associated with negative health effects, such as that of the Western
diet [131]. Of course, it is the ideals of the Mediterranean diet that are important to follow, as a
traditional Mediterranean diet is practically nonexistent these days, and countries of the Mediterranean
follow a diet more closely related to the Western diet than that of their ancestors [129]. Most national
dietary guidelines follow similar principals to the Mediterranean diet by promoting the intake of fruit
and vegetables, etc., in large quantities and advise that people limit their intake of processed foods.
5.1.2. Western Diet
The “Western” dietary pattern, prevalent in developed countries, is characterized by high
consumptions of processed foods such as refined grains, cured and red meats, desserts and sweets,
deep-fried foods, and high-fat products [132]. As a result, there is a high intake of sugars, saturated
fats, and refined carbohydrates that may be associated with hyperglycemia and hyperlipidemia.
Consequently, there is a high prevalence of type II diabetes mellitus and obesity, thus potentially
putting these particular populations at increased risk for severe COVID-19 complications [133].
The Western diet is highly associated with hyperglycemia and advanced glycation end products
(AGEs) that are linked with inflammation, metabolic complications, and chronic disease [134]. Notably,
hyperglycemia is a risk factor associated with high mortality in patients with severe COVID-19
infection [135]. This pattern of intake has also been associated with an increased risk of asthma in
children [136]. In adults, a Western diet has been shown to be positively associated with an increased
frequency of asthma exacerbation [137]. This dietary pattern is also associated with other inflammatory
conditions [138] due to the relative absence of the beneficial nutrient components that are present in
the Mediterranean diet and other healthy dietary patterns. Similarly, before the pandemic, the advice
was that people should avoid following dietary patterns consistent with the Western diet due to the
profound negative health effects associated with its adherence, including the development of NCDs
and the promotion of a low-grade inflammatory state.
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5.2. Foods, Food Groups, and Individual Nutrients
5.2.1. Fruit and Vegetables
Fruit and vegetable intakes have been investigated for potential benefits in association with
respiratory [139] and inflammatory [140] conditions due to their nutrient profile consisting of
antioxidants, vitamins, minerals, and phytochemicals that include phenolic compounds that can
exert antioxidant, anti-inflammatory, and other beneficial effects [123,141,142]. Indeed, polyphenols
may also exhibit antiviral effects against the West Nile virus, Zika virus, and Dengue virus [143,144].
A recent umbrella review of research on fruits, vegetables, and health [145] provides support for
the dietary recommendation “to consume four or more servings per day” in this context; however,
excessive intakes may also displace other valuable foods, potentially leading to nutrient deficiencies of
some vitamins or minerals not found in these foods. For example, zinc is more prevalent in meat or
dairy products. Fruits and vegetables are also sources of fiber important for gut health. Many of the
beneficial components of fruits and vegetable will be further discussed in Section 5.3.
5.2.2. Fish and Fish Oils
Fish and fish oils have been associated with various health benefits against numerous NCDs, including
CVD and cancer [146–149]. Omega-3 polyunsaturated fatty acids (PUFA), namely eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) from fish, other marine sources, and supplements, have been
shown to be anti-inflammatory through several cellular mechanisms, including their incorporation into
cellular membranes and resulting altered synthesis of eicosanoids [146,147]. Li et al. [148] reviewed
89 systematic reviews and meta-analyses investigating fish intake and all-cause mortality, concluding
that fish intake at 2–4 servings per week is associated with the largest risk reduction.
However, despite these potential positive effects, there is conflicting evidence in relation to fish or
fish oil consumption for some viral infections. In influenza models, fish oil-fed mice demonstrated
impaired resistance to influenza infection due to their immunomodulatory and anti-inflammatory
properties, which negatively dampened the immune response of the mice against the infection [150].
Indeed, in another mouse model, fish oil intake delayed influenza virus clearance and impaired
the immune response in the lungs of mice by disrupting interferon-γ and immunoglobulin A [151].
A further study indicated that it may be due to the impairment of virus-specific T lymphocyte
cytotoxicity [152]. However, substantial human trials in this area are lacking. In contrast, EPA and
DHA may act as substrates for the synthesis of specialized pro-resolving lipid mediators such as
maresins, resolvins, and protectins, of which protectins may reduce the replication of influenza [153]
and potentially affect the inflammatory manifestations of respiratory viral diseases [154]. Although
their synthesis via fish oil supplementation in humans requires further investigation, as there are
differing reports of their clinical relevance [79,155,156].
Prostaglandins, thromboxanes, and leukotrienes are proinflammatory molecules formed from
arachidonic acid (AA). Suppressing prostaglandin synthesis by targeting the cyclooxygenase enzymes
(COX-1 and COX-2) with nonsteroidal anti-inflammatory drugs (NSAIDs) reduces inflammation, pain,
and fever. However, using COX-1/2 inhibitors in some viral infections such as influenza A may have
differential and potentially negative effects, as demonstrated in vivo [157]. Previously, it was shown
that SARS-CoV-1 could bind with the COX-2 promotor, increasing its expression [158]. However,
it is not currently known whether NSAIDS may be beneficial or lead to more severe COVID-19
symptoms, as prostaglandins such as prostacyclin (PGI2), prostaglandin E2 (PGE2), and prostaglandin
D2 can both reduce and induce inflammation [159]. Certainly, it has been suggested that selective
inhibition human microsomal prostaglandin E synthase 1 (mPGES-1) may be a viable therapeutic
target for SARS-CoV-2 [160]. While it is known that n-3 fatty acids can beneficially interact with the
COX enzymes [146,161], it also is not clear if fish or fish oil consumption may be beneficial against
SARS-CoV-2 infection.
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In terms of dietary strategies, it is known that marine n-3 PUFA can replace AA in the phospholipids
of cell membranes, thus affecting eicosanoid and prostaglandin synthesis. Indeed, the supplementation
of EPA and DHA raises the level of these fatty acids in the phospholipids of cells involved in
inflammation in a time and dose-dependent fashion at the expense of AA [146]. There is the potential
that AA, EPA, DHA, and other dietary unsaturated fatty acids can inactivate enveloped viruses. It is
thought that these fatty acids and others cause leakages or lysis of the viral envelopes by disrupting
the membrane integrity, amongst other potential mechanisms [162–165]. Indeed, alveolar immune
cells such as macrophages, leukocytes, natural killer cells, and B and T cells release unsaturated fatty
acids such as AA into the surrounding microenvironment when challenged by viruses, including
SARS-CoV-1, MERS, and, potentially, SARS-CoV-2 [162]. Notably, an in vitro model of human cells
(Huh-7 and VeroE6) infected with a human coronavirus (HCoV-229E) demonstrated that several
bioactive lipids downstream of phospholipase A2 (PLA2) activation were upregulated by the host cells.
It is postulated that coronaviruses modulate the host lipid profile to optimize and maintain a specific
homeostasis for viral replication. However, exogenous supplementation of AA and linoleic acid
suppressed viral replication by interfering with the optimal host lipid conditions for viral replication.
Notably, exogenous supplementation of AA and linoleic acid was also conserved when human cells
were infected with MERS [166]. EPA, DHA, and AA also inhibited the replication of enterovirus A71
and coxsackievirus A16 [167]. While it is suggested that the oral or intravenous administration of
various bioactive lipids could potentially reduce the severity and/or enhance the recovery of those
infected with COVID-19 [162], a dietary prophylactic approach or a dietary strategy for recovering
patients is also worth considering. Further research is certainly required, as increasing AA via the diet
might seem counterintuitive, as it is mainly proinflammatory, and it is associated with the Western
diet [168], but EPA and DHA could be considered.
Most fish oil studies were conducted using EPA and DHA, which have previously exhibited
immunomodulatory effects [169], but it is worth noting that other lipid molecules in fish, including polar
lipids, exhibit anti-inflammatory effects through differing mechanisms by modulating the activities
and metabolism of the potent proinflammatory and prothrombotic mediator platelet-activating factor
(PAF) [146,170]. Certainly, PAF and its receptor (PAF-R) are known to be involved several NCDs [87]
and viral infections such as HIV [50], dengue virus [171,172], respiratory syncytial virus [173], and lung
injury caused by influenza A [174]. Indeed, a lipidomic analysis of in vitro human cells infected with a
coronavirus (HCoV-229E) demonstrates a 3.5-fold elevation of PAF levels [166]. Blockade of the PAF-R
pathways with PAF antagonists prevented severe disease manifestations in the dengue virus [171].
Similarly, PAF-R antagonism in mice suffering influenza A induced protection against lung injury and
mortality [174]. In addition, evidence in humans shows that highly active antiretroviral therapy with
anti-PAF effects may attenuate PAF metabolism in the blood of HIV patients [49,50]. PAF-R antagonists
have also been investigated for their anti-inflammatory effects in HIV-1-associated neurocognitive
disorders [175]. Therefore, dietary PAF inhibitors such as polar lipids in fish [146], or even other dietary
sources [147,176–178], may exhibit anti-inflammatory effects that may be beneficial in viral diseases
and NCDs, as opposed to PUFA esters or fatty acids that act through differing mechanisms.
Fish and other foods also contain polar lipids that exhibit potent antithrombotic effects against
PAF and other prothrombotic pathways, including thrombin, collagen, and adenosine diphosphate
(ADP) [146,179,180]. Other bioactive compounds in fish, such as peptides, may also prevent against
thrombosis, the generation of ROS, and hypertension [124,181]. Therefore, increasing fish consumption
may provide the nutrients and bioactive molecules that may influence some of the pathomechanisms
and complications of COVID-19, such as inflammation and thrombosis. Currently, 2–4 g of n-3 fatty
acids seem to be physiologically relevant against hypertension, inflammation, and thrombosis; however,
even higher doses have been suggested [146,182–184]. Studies are warranted to discern whether fish
consumption may beneficially support immune function against COVID-19.
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5.2.3. Vitamin C
Vitamin C (ascorbic acid) is a water-soluble vitamin, the consumption of which has been part
of cultural practice when suffering with a cold or flu for decades. This is due to research published
by Nobel prize winner Linus Pauling (circa 1970) theorizing how vitamin C helps to treat colds [185].
An analysis of 29 studies including 11,306 participants concluded that supplementing with 200 mg or
more of vitamin C does not reduce the risk of contracting a cold [186,187]. However, regular vitamin C
supplements had several benefits, including:
• Reduced cold severity: They reduced the symptoms of a cold, making it less severe.
• Reduced cold duration: Supplements decreased the recovery time by 8% in adults and 14% in
children, on average [187].
Indeed, a supplemental dose of 1–2 g was enough to shorten the duration of a cold by 18% in
children, on average [186]. Despite much of the research on vitamin C intake being conducted using
supplements, vitamin C can also be obtained through dietary sources such as citrus fruits, berries,
brassicas, leafy greens, tomatoes, and various other fruits and vegetables. Fresh fruit consumption
high in vitamin C, even at low levels, was associated with a reduction of wheezing symptoms in
children in a cross-sectional study [188]. Interestingly, most studies examining vitamin C intakes
fail to account for dietary vitamin C intakes in their trial design [189], potentially contributing to
the disparity of outcomes observed at a grand scale [186]. As reviewed by Hemilä [190], there is a
dose-concentration relationship, whereby healthy individuals may not benefit from supplementation
if the dietary intake of vitamin C is 200 mg/day. However, this does not apply to all situations
and certainly not in the case of patients with infections, as they have lower vitamin C levels due to
alterations in the metabolism [190]. Although evidence is currently weak in relation to the utility
of vitamin C against COVID-19 infections [191], there was sufficient evidence from investigations
of vitamin C in other respiratory diseases to begin conducting clinical trials for severe hospitalized
cases (www.clincialtrials.gov: NCT04264533). Currently, the recommended daily allowance (RDA)
of vitamin C for healthy adults according to the United States National Institute of Health (NIH)
dietary reference index (DRI) is 75–90 mg/d (tolerable upper intake level is 2 g/d) [192]. Due to a lack
of evidence against COVID-19, there are limited recommendations for vitamin C intake. However,
previously, doses of 1–2 g/d were effective in preventing upper respiratory infections. As those levels
are not attainable through dietary sources, supplementation may be advised for those at a higher risk
of respiratory infections. However, as previously discussed, doses above 200 mg/day might not benefit
healthy individuals.
5.2.4. Vitamin D
The data on vitamin D and immune function is also equivocal. Vitamin D is often referred to
as the sunshine vitamin; it is also found in eggs, mushrooms, fatty fish such as salmon, milk and
dairy products, or foods fortified with vitamin D. A recent analysis of 25 randomized controlled
trials of 11,000 patients showed an overall protective effect of vitamin D supplementation against
acute respiratory tract infections [193]. The research is not conclusive, and some studies of vitamin
D have not shown any benefit. On balance, Vitamin D supplementation was safe, and it protected
against acute respiratory tract infection overall. Patients who were very vitamin D-deficient and
those not receiving bolus doses experienced the most benefits. Recent research has suggested that
increasing vitamin D intakes may reduce the risk of infections and, also, COVID-19 [33]. The authors
speculate that low vitamin D levels may play a role in the high incidences of COVID-19, as the
outbreak occurred in winter. Indeed, several research groups have speculated the same and considered
whether latitude plays a role in infection susceptibility [194]. Researchers have also highlighted
the need for vulnerable groups to maintain their vitamin D status to reduce the risk of respiratory
infections, including COVID-19, through various mechanisms [195,196]. Moreover, a trial is currently
underway (www.clinicaltrials.gov: NCT04334005) with the aim of assessing the utility of vitamin D as
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an immune-modulating agent. Patients will be monitored to see if there is an improvement of health
status in nonsevere symptomatic patients infected with COVID-19, as well as determining if vitamin D
could prevent patient deterioration. Vitamin D itself may exhibit antiviral effects by interfering with
viral replication and through its immunomodulatory and anti-inflammatory properties [197]. As a
result, it is assumed that increased vitamin D may provide benefits against SARS-CoV-2 infection [198].
Patients in Switzerland that tested positive for SARS-CoV-2 had significantly lower 25-hydroxyvitamin
D levels (p = 0.004) (median value 11.1 ng/mL) compared with negative patients (24.6 ng/mL), which
was also confirmed by stratifying patients according to age >70 years [199]. However, a recent
analysis of the UK Biobank provided no evidence to support a potential role for the concentration
of 25-hydroxyvitamin D as an explanation for the increased susceptibility of individuals positive for
COVID-19 infection. However, they did discern that COVID-19 disproportionately affected Blacks and
minority ethnic populations independent of vitamin D levels [78].
Consequently, further research is required before any determination can be made about the
prophylactic or therapeutic values of vitamin D against COVID-19. The RDA of vitamin D for healthy
adults according to the NIH DRI is 15–20 µg/d (600–800 IU; tolerable upper intake level 100 µg/d or
4000 IU) [200]. However, researchers recommend doses of 10,000 IU/d (250 µg/d) of vitamin D3 for
several weeks to quickly raise 25-hydroxyvitamin D concentrations, followed by 5000 IU/d (125 µg/d)
in order to maintain concentrations above 40–60 ng/mL (100–150 nmol/L), which may be beneficial
against COVID-19. Higher doses of vitamin D are certainly advisable for vulnerable individuals. It
is also particularly important to increase dietary sources of vitamin D at this time, as many globally
are subjected to less sun exposure due to “stay at home” mitigation strategies. Although it is unclear
whether the extreme doses suggested would be beneficial against COVID-19, it is clear that they are
unattainable through dietary means and would require supplementation.
5.2.5. Vitamin E
Vitamin E is a group of fat-soluble antioxidants that includes molecules such as tocopherols and
tocotrienols. However, α-tocopherol is the only form of vitamin E recognized to meet human
requirements. α- and γ-tocopherols are both abundant forms of dietary vitamin E. However,
α-tocopherol is approximately 5 to 10-fold higher than γ-tocopherol in circulation due to the differences
in bioavailability and metabolism [32]. Various foods provide vitamin E: nuts, seeds, and vegetable
oils are significant contributors to dietary intakes, as well as green leafy vegetables and fortified
cereals [32,201]. Numerous animal and human studies reviewed by Wu and Meydani [202] have
indicated that vitamin E deficiency impairs both humoral and cell-mediated immune functions. It is
generally accepted that vitamin E may exert its immunoenhancing effects by scavenging oxygen species
to reduce oxidative stress [201], and it may induce anti-inflammatory effects [202]. Vitamin E can also
protect the polyunsaturated fatty acids (PUFAs) in the cell membranes from oxidation, regulate the
production of ROS and reactive nitrogen species (RNS), and modulate signal transduction. Likewise,
vitamin E is present in high concentrations in immune cells, which protects them from oxidative
damage due to their high metabolic activity and PUFA contents [32,203]. Notably, aging is associated
with dysregulation of the immune system, predisposing people to increased oxidative stress and
inflammation. This leads to increased incidences of infections in the elderly, such as influenza. Despite
the fact that the elderly have comparable vitamin E levels to younger individuals, increasing vitamin E
intakes may benefit their immune function, impart resistance to infection, and reduce morbidity due to
infections [204–206]. As the elderly are predisposed to infection due to immunosenescence [207], it is
worth investigating vitamin E for potential benefits against COVID-19. Indeed, it has been suggested
that a combination of vitamins C and E may be a useful antioxidant therapy for cardia complications
of COVID-19 [81]. However, there is little evidence to date on the utility of vitamin E as a prophylactic
or therapeutic agent against COVID-19. The RDA of vitamin E for healthy adults according to the NIH
DRI is 15 mg/d (tolerable upper intake level 1000 mg/d) [192]. While vitamin E has been recommended
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as a potentially beneficial nutrient against COVID-19 infection [82], there are currently no estimates of
a beneficial dosage.
5.2.6. Zinc
Zinc is a trace element of the diet that is critical to the development of immune cells and an
important cofactor for many enzymes [208]. Zinc deficiency can contribute to defective cell-mediated
immunity and to increased susceptibility to various infections, including pneumonia [209,210]. Despite
various foods containing zinc, including meat, dairy, and legumes, etc. [211–213], the majority of
dietary zinc research has focused on zinc supplementation. Therefore, it is not clear from dietary
studies high in zinc if increased zinc intake can protect against the effects of viral infections. Indeed,
zinc supplements and lozenges are a popular remedy for fighting off colds and respiratory illnesses.
Some studies have found that zinc lozenges may reduce the duration of a cold by about a day and
may reduce the number of upper respiratory infections in children [214]. The data on zinc are mixed,
and further research is necessary to support a supplementation policy. It has certainly been suggested
that increasing zinc intakes may be useful against COVID-19 infections by reducing viral replication
and reducing the effects of the gastrointestinal and lower respiratory symptoms [89]. While the
RDA of zinc according to the NIH DRI is 8–11 mg/d of zinc for adults (tolerable upper intake level
40 mg/d) [215], it has been suggested that a zinc intake of 30–50 mg/d might aid in the control of RNA
viruses such as influenza and coronaviruses [115].
5.2.7. Copper
Copper is recognized as an essential trace element; food groups such as offal and nuts and, to a
lesser extent, cereals and fruits can be regarded as suitable dietary sources [216]. Copper is one of many
dietary minerals, including zinc, that are essential to maintaining the integrity of DNA by preventing
oxidative DNA damage [217]. Copper deficiency has been associated with altered immune responses
and an increased frequency of infections [218]. Mechanistically, copper deficiency can occur following
chronic TNF-α-induced inflammation of the lungs, and it is proposed that copper supplementation
may ameliorate this lung inflammation in mice [219]. However, high levels of serum copper have
been associated with adverse effects on respiratory health in humans [220]. Regardless of these
inconsistencies, Bost et al. and ViXas et al. [216,221] have presented reviews relating to the adequacy of
copper intake in developed countries. They have found that adults and elderly populations generally
meet dietary recommendations. As a result, a widespread adherence to healthy eating guidelines
should achieve sufficiency. The RDA of copper according to the NIH DRI is 900 µg/d for adults
(tolerable upper intake level 10 mg/d) [215]. While there has been no recommended dietary intake of
copper against COVID-19, a copper intake of 7.8 mg/d has been shown to reduce oxidative stress and
alter immune function, albeit it is unknown whether those changes were beneficial [222]. Therefore,
considerably more research is required to determine whether higher intakes of dietary copper may
benefit immune functions against viral infections.
5.2.8. Fiber
Studies demonstrate a lower incidence of bacterial translocation across the gut barrier with the
administration of dietary fiber [223], suggesting that this nutrient modulates immunity. Among
the potential mechanisms by which dietary fiber influences the immune system are changes to the
gut-associated lymphoid tissues (GALT) arising from altered gut microflora. Prebiotic fiber is neither
hydrolyzed nor absorbed in the upper part of the gastrointestinal tract and becomes a selective
substrate for one or a limited number of beneficial colonic bacteria [224,225]. Indeed, fiber intake has
been shown to increase the survival of influenza-infected mice via various mechanisms, including
blunting the immune response by altering the type of immune cells generated and the generation of
diet-derived short-chain fatty acid (SCFA)-enhanced CD8+ T cell effector functions by altering the
cell’s metabolism [226]. Western diets are often deficient of dietary fiber [138]; therefore, increasing
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the consumption of both soluble (oat bran, barley, nuts, seeds, beans, lentils, peas, and some fruits
and vegetables) and insoluble (wheat bran, vegetables, and whole grains) sources of fiber to the
recommended 25–38 g/day is advisable [227]. Currently, there are no recommendations for fiber
intake during the pandemic, but higher intakes may not be advisable due to the potential risk for
gastrointestinal issues.
5.3. General Dietary Advice during the COVID-19 Pandemic
While the Mediterranean diet, various food groups, and nutrients are just some of the examples
of how nutrition plays an important role in modulating our immune health and preventing the
development of NCDs, most international nutritional guidelines follow similar patterns, whereby they
promote the high intake of fruits and vegetables and healthy quantities of the other food groups to
provide all the essential nutrients for health. Hence, following any healthy diet at this time that provides
an adequacy of RNIs will support immune function. However, there is concern that people who are
deficient in some micronutrients such as vitamin C, vitamin D, or zinc may warrant supplementation
or modify their dietary patterns to maintain a nutritional status and support healthy immune function.
This is particularly important for our vulnerable populations, including the elderly and those with
NCDs. Indeed, as many countries have imposed guidelines for people to “stay in place” and limit
travel, etc., it is important for everyone to consider vitamin D levels when exposure to sunlight will be
limited at this time [33,196]. Likewise, although not always possible depending on an individual’s
personal circumstances, maintaining activity or moderate exercise at this time may be beneficial in
supporting immune health [228]. Exercise in any form, even within the home, will help to maintain
one’s health, as a lack of exercise could significantly affects a person’s cardiovascular risk in the
future [106]. However, exercise may not be advisable for symptomatic COVID-19 patients, not only to
reduce the transmission of the virus but, also, because some COVID-19 infections exhibit rare cardiac
complications that could be aggravated by physical exertion [229].
Due to the “stay in place” guidelines, it is also important to consider boredom and stress at this
time, as they are associated with increased food consumption, which can lead to people inadvertently
seeking comfort during times of stress, like this current pandemic [126,230,231]. Sleep disturbances are
also likely during isolation; thus, it is important to follow a normal sleep cycle if possible, along with
promoting following normal eating patterns to promote the synthesis of melatonin and serotonin at
dinner [126]. In particular, the WHO provides sound and practical advice to all on how to manage
your health in terms of nutrition and wellbeing during self-quarantine [232].
It has been observed that many patients presenting to hospitals with COVID-19 infections have
severe anorexia, inflammation, and markers of malnutrition. These additional vulnerabilities may
increase risks for respiratory failure, necessitating noninvasive ventilation [83]. Furthermore, prolonged
hospitalization may be accompanied by decreases in weight and muscle mass, which will further
disadvantage at-risk patients [233,234]. Therefore, it is important to enhance nutrition to improve
the response to therapy [235]. Two different Italian research consortia have proposed nutritional
interventions: one to non-critically ill hospitalized COVID-19 patients [83] and the other for those
who are hospitalized, severely ill, and may require enteral nutrition [235]. Both aim to increase the
likelihood of beneficial clinical outcomes for hospitalized patients. Certainly, considering severe and
nonsevere patient nutrition during hospitalization and interventions for those who recover from
COVID-19 infections is of considerable importance and requires further research.
A final consideration to make is that there is a significant increase in pseudoscience and
misinformation surrounding potential treatments and supplements to fight the COVID-19 infection.
The authors would like to express again that there is currently no known effective treatment or mitigation
strategy against COVID-19. Indeed, it has been recognized by others that there is considerable
“emerging quackery” in relation to various foods and nutraceuticals with purported benefits and
immune-enhancing supplements that may prevent or even cure the COVID-19 infection. This is
symptomatic of levels of desperation and anxiety surrounding the crisis [236]. Consequently, it is
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important that pseudoscientific and false claims associated with nutritional products are avoided by
manufacturers and reported to the relevant authorities to protect the health of those most vulnerable
and susceptible within our communities.
6. Conclusions
The COVID-19 pandemic is a significant threat to human life worldwide. As there is no known
effective cure or treatment for COVID-19 yet, all potential therapeutics, mitigation interventions,
and prevention strategies that may reduce the incidence or severity of infection are of vital importance.
In this review, inflammation associated with pre-existing comorbidities was highlighted as a significant
risk factor for COVID-19 patients. As a result, some of the anti-inflammatory therapies currently
under investigation were discussed. Likewise, the potential role of a person’s nutritional status
and nutrients and foods that may exert anti-inflammatory and immunomodulatory effects were
explored, as summarized in Figure 3. Nutrients such as vitamin C, vitamin D, and zinc may hold some
promise for the treatment of COVID-19. Likewise, nutrients with anti-inflammatory, antithrombotic,
and antioxidant properties may prevent or attenuate the inflammatory and vascular manifestations
associated with COVID-19. Indeed, following healthy dietary patterns and avoiding unhealthy dietary
patterns, such as the Mediterranean and Western diets, respectively, may have beneficial effects against
infection but require significantly more research. Our primary conclusion is that it is vitally important
to maintain a healthy diet and lifestyle during the pandemic. This is especially important for the
vulnerable in our society. In particular, those at high risks of infection should at least maintain their
nutritional status by ensuring they reach their RDA of the potentially beneficial nutrients outlined
in this review. Certainly, governments should actively encourage healthy eating and exercise in
conjunction with the guidance provided on personal hygiene and physical distancing. That being said,
various socioeconomic issues, lifestyle constraints, access to food, financial problems, or “stay in place”
mitigation guidelines may reduce one’s ability to achieve this. Further research and review of the
topics discussed in this manuscript are required as research evolves during the pandemic to discern
the effective and ineffective strategies implemented globally.
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antithrombotic, and antioxidant properties may prevent or ttenuate the inflammatory and ascular 
manifestations associated with COVID-19. Indeed, following healthy dietary patterns and avoiding 
unhealthy dietary patterns, such as the Mediterranean and Western diets, respectively, may have 
beneficial effects against infection but require significantly more research. Our primary conclusion is 
that it is vitally important to maintain a healthy diet and lifestyle during the pandemic. This is 
especially important f r the vulnerable in our society. In particula , those at high risks of infection 
should at least maintain their nutritional status by ensuring they reach their RDA of the potentially 
beneficial nutrients outlined in this review. Certainly, governments should actively encourage 
healthy eating and exercise in conjunction with the guidance provided on personal hygiene and 
physical distancing. That being said, various socioeconomic issues, lifestyle constraints, access to 
food, fina cial problems, o  “s ay in place” mitigation guidelin s may reduce one’s ability to achieve 
this. Further research and review of the topics discussed in this manuscript are required as research 
evolves during the pandemic to discern the effective and ineffective strategies implemented globally.  
 
Figure 3. A representation of the inflammatory molecules involved in infection and how certain 
dietary components may interact with them. Included are the cytokines, growth factors, and other 
chemokines that promote the onset and progression of inflammatory manifestations, dysregulation 
of the immune system, and a diseased state due to the effects of several unmodifiable and modifiable 
risk factors. Targeted drug treatments and/or healthy lifestyle choices such as balanced diets and 
physical activity can counterbalance such inflammatory manifestations towards homeostasis. 
Figure 3. A representation of the inflammatory molecules involved in infection and how certain dietary
components may interact with them. Included are the cytokines, growth factors, and other chemokines
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that promote the onset and progression of inflammatory manifestations, dysregulation of the immune
system, and a diseased state due to the effects of several unmodifiable and modifiable risk factors.
Targeted drug treatments and/or healthy lifestyle choices such as balanced diets and physical activity
can counterbalance such inflammatory manifestations towards homeostasis.
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